Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Datopotamab deruxtecan is in development for the treatment of patients with previously untreated, locally recurrent inoperable or metastatic triple negative breast cancer (TNBC), who are not suitable candidates for PD-1/PD-L1 inhibitor therapy. TNBC is a subtype of breast cancer which lacks hormone receptor expression. The risk factors for TNBC include a history of breast disease and radiation therapy, family history of TNBC, alcohol intake, smoking, exposure to carcinogenic chemicals, and the intake of processed food. TNBC signs and symptoms include lump or thickening in the breast or armpit, changes in the position of the nipple such as an inverted nipple, and changes in the skin of the breast such as redness, rash, puckering or dimpling of the skin. Chemotherapy is the main form of treatment for patients with TNBC, however, the effectiveness of chemotherapy for TNBC remains limited.